Integral Derivatives’s Bristol-Myers Squibb BMY Stock Holding History

Integral Derivatives’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	$1.49M	Sell	23,500 -37,800	-62%	-$2.43M	0.04%	168
2017 Q4	$3.76M	Buy	61,300 +16,300	+36%	+$1.02M	0.07%	165
2017 Q3	$2.87M	Buy	45,000 +12,600	+39%	+$736K	0.05%	230
2017 Q2	$1.8M	Sell	32,400 -33,100	-51%	-$1.8M	0.04%	326
2017 Q1	$3.56M	Buy	65,500 +8,100	+14%	+$444K	0.06%	184
2016 Q4	$3.35M	Buy	57,400 +100	+0.2%	+$5.47K	0.06%	200
2016 Q3	$3.09M	Buy	57,300 +47,400	+479%	+$3.04M	0.06%	183
2016 Q2	$728K	Buy	9,900 +4,400	+80%	+$311K	0.02%	502
2016 Q1	$351K	Sell	5,500 -51,600	-90%	-$3.25M	0.01%	600
2015 Q4	$3.93M	Buy	57,100 +22,500	+65%	+$1.49M	0.1%	163
2015 Q3	$2.05M	Buy	34,600 +4,200	+14%	+$266K	0.06%	292
2015 Q2	$2.02M	Buy	30,400 +7,500	+33%	+$494K	0.06%	314
2015 Q1	$1.48M	Sell	22,900 -22,600	-50%	-$1.41M	0.03%	381
2014 Q4	$2.69M	Buy	45,500 +8,300	+22%	+$468K	0.05%	338
2014 Q3	$1.9M	Buy	37,200 +200	+0.5%	+$9.99K	0.03%	489
2014 Q2	$1.79M	Buy	37,000 +2,300	+7%	+$113K	0.03%	473
2014 Q1	$1.8M	Buy	34,700 +23,100	+199%	+$1.23M	0.03%	452
2013 Q4	$617K	Buy	+11,600	New	+$591K	0.01%	969

Other funds holding BMY

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Integral Derivatives's BMY Position: Q2 2017 in Review

Integral Derivatives sold out of Bristol-Myers Squibb (BMY) in Q2 2017, closing a stake of 20,436 shares — an estimated $1.11M sold.

Integral Derivatives first reported a position in BMY in Q4 2013 and held it in 7 quarters. The position peaked at $2.08M in Q2 2014. 1,594 funds tracked by Wall St. Rank hold BMY as of Q2 2017.

Integral Derivatives reported no remaining Bristol-Myers Squibb position as of Q2 2017 after selling out during the quarter.
Integral Derivatives sold 20,436 Bristol-Myers Squibb shares in Q2 2017, an estimated $1.11M.
Integral Derivatives first reported a position in Bristol-Myers Squibb in Q4 2013 and held it in 7 quarters.
Integral Derivatives's Bristol-Myers Squibb position peaked at $2.08M in Q2 2014.
1,594 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2017.

Based on Integral Derivatives's 13F filing for Q2 2017, filed 14 Aug 2017.